Herbostroiodine, a novel, herbal-based radioprotective compound.
Radiotherapy has severe side effects for cancer patients. Herbostroiodine helps to reduce the side effects of radiotherapy by removing unneeded radio-drug.
The Problem
Cancer patients undergoing radiation therapy often suffer severe side effects due to collateral damage of surrounding tissue. Radioprotective drugs are currently very limited and often have severe side effects without efficacy. The existing treatments are often chemically harsh, expensive, and lack long-term safety data. There’s a pressing need for natural, non-toxic solutions that can protect healthy cells and potentially fight cancer itself and lead to an improved clearance of unlocalized radioisotopes.
The Solution
SEBREH’s Herbostroiodine, is a novel, herbal-based radioprotective and anti-cancer compound. It has shown effectiveness in the context of iodine and strontium radioisotope treatments. It is formulated from natural sources and enhanced with cold plasma technology for increased bioavailability and efficacy, Herbostroiodine aims to protect healthy tissues during radiation therapy while exhibiting anti-tumor activity.
The Opportunity
The radiotherapy market for cancer through radioisotope in 2024 was just under $8 billion with an expected CAGR of 7% and reaching about $13 billion in 2031. The need for adjunctive therapies that reduce radiation side effects will increase accordingly. With an increasing demand and desire for natural, safe, and sustainable solutions in healthcare and food safety, SEBREH is uniquely positioned to license Herbostroiodine to pharma and biotech partners.
Status
SEBREH’s Herbostroiodine is in the early validation phase with promising biological results. Patent applications have been filed due protect the IP and are actively prosecuted. The next steps are formalized preclinical studies around efficacy, toxicology, and pharmacokinetics leading to an IND submission. R&D, regulatory approval, and pilot partnerships.
Meet the Team
Sara Sheiklary
College of Engineering
Peter Nestler PhD
Tech Launch Arizona
Check out more Pharma startups.
View All Startups & Inventions
Precision anti-infective technology focused on a microbiome sparing strategy. We target Clostridioides difficile infection (CDI), an antibiotic-associated infectious diarrheal disease, through oral delivery of a targeted Antisense Oligonucleotide.
Safe Lactobacillus-based synthetic biologic as a colonization resistance agent of, and oral vaccine for, Clostridioides difficile infection (CDI).
Our data-driven platform integrates high-throughput analytics and AI for next-generation drug discovery. We leverage novel insights into the foundational biologic pathways of neurodegenerative diseases to discover, evaluate, and develop disease-modifying therapeutics for Alzheimer’s disease, frontotemporal dementia (FTD) , amyotrophic lateral sclerosis (ALS), and other degenerative diseases of the nervous system.
We offer a novel topical treatment for ocular degeneration that restores neuronal function and vision with a simple eye drop.
